Schering-Plough slashes jobs

Oh, the curse of duplication. Schering-Plough embarked on a company-wide downsizing yesterday, eliminating hundreds of jobs in nearly all departments, including finance, research, information technology, and marketing. The reason? Schering's $14 billion acquisition of Organon Biosciences, which wrapped up in November.

A company spokeswoman told Pharmalot that "a number" of jobs had been cut in the process of integrating the two companies, but didn't specify how many.

- read the item at Pharmalot

Related Articles:
Top 8 layoffs of 2007. Report
Schering-Plough: A good company to work for. Report
Organon experiences Schering's research 'religion'. Report
Schering-Plough pays $14.4B for Organon. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.